InsiderTrades

ARCH Venture Fund XII, L.P.

SEC CIK 1906837 · EDGAR

Buying vs selling by month open-market trades, last 35 months, all 2 companies
BoughtSold

Companies

TickerCompanyTitleHoldingBoughtSoldTradesFirstLast
PRMEPrime Medicine, Inc.10% 6.23M $10.00M — 12025-08-012025-08-01
NMRANeumora Therapeutics, Inc.10% 4.13M $1.96M — 22023-11-082023-11-13

Most active insiders at PRME, 12 months

#InsiderTitleBoughtSold
No open-market trades in the last year.

ARCH Venture Fund XII, L.P. made no open-market trades at PRME in the last 12 months.

Transactions 3

Type
Reset
X Filed Traded Ticker Company Insider Title Type Price Qty Owned ΔOwn Value
I 2025-08-01 2025-08-01 PRME Prime Medicine, Inc. ARCH Venture Fund XII, L.P. 10% P - Purchase $3.30 +3.03M 6.23M +95% +$10.00M
MI 2023-11-15 2023-11-13+ NMRA Neumora Therapeutics, Inc. ARCH Venture Fund XII, L.P. 10% P - Purchase $11.77 +35.0K 4.13M +0.9% +$412.1K
MI 2023-11-13 2023-11-08+ NMRA Neumora Therapeutics, Inc. ARCH Venture Fund XII, L.P. 10% P - Purchase $10.98 +140.6K 4.10M +4% +$1.54M

Purchase Sale Sale after option exercise All abbreviations